{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:49:42Z","timestamp":1785149382520,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Asahi Kasei Medical Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites, but adverse events, such as fever, are problematic. Several cytokines have been suggested to be responsible for the adverse events, but they have not been investigated in detail. Thus, we comprehensively analyzed cytokines in ascites fluid (AF) and serum before and after CART to determine the influence of cytokines on the safety and efficacy of CART.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thirteen ovarian cancer patients with refractory malignant ascites who underwent CART were enrolled. We comprehensively analyzed 27 cytokines in AF and serum before and after CART. Simultaneously, vital measurements, blood tests, adverse event recordings, and QOL assessments were performed to examine the relationships between the cytokines in AF and serum.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Interleukin (IL)-5, IL-6, IL-10, and monocyte chemoattractant protein-1 levels were increased in the concentrated AF and in the serum immediately after reinfusion, but they decreased after 24\u00a0h. Body temperature also increased immediately after reinfusion, and decreased after 24\u00a0h. The CRP level at 24\u00a0h after reinfusion was increased, and was positively correlated with the IL-6 level. A QOL assessment using the Cancer Fatigue Scale revealed significantly lower scores after CART.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results indicate that the cytokine-induced fever and increased inflammatory response after CART were temporary, and that CART is safe. Additionally, QOL improved after CART. Thus, CART appears safe and effective for treating patients with refractory cancerous ascites.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10147-024-02682-1","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T21:38:32Z","timestamp":1736026712000},"page":"559-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Rikako","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-1015","authenticated-orcid":false,"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-4649","authenticated-orcid":false,"given":"Takayuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-3333","authenticated-orcid":false,"given":"Tadahiro","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-6688","authenticated-orcid":false,"given":"Takashi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9126-3361","authenticated-orcid":false,"given":"Yasuhisa","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-3747","authenticated-orcid":false,"given":"Tsukasa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"2682_CR1","unstructured":"Global Cancer Observatory. Cancer today dataviz. Globocan2022\u201408.02.2024. https:\/\/gco.iarc.who.int\/today\/en\/dataviz. Accessed 7 Sept 2024"},{"key":"2682_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/cmar.s100210","volume":"9","author":"M Stukan","year":"2017","unstructured":"Stukan M (2017) Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res 9:115\u2013130. https:\/\/doi.org\/10.2147\/cmar.s100210","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2682_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-021-02077-6","volume":"27","author":"K Matsusaki","year":"2022","unstructured":"Matsusaki K, Aridome K, Emoto S et al (2022) Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021). Int J Clin Oncol 27(1):1\u20136. https:\/\/doi.org\/10.1007\/s10147-021-02077-6","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"2682_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF et al (2020) The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 123(1):9\u201316. https:\/\/doi.org\/10.1038\/s41416-020-0875-x","journal-title":"Br J Cancer"},{"issue":"6","key":"2682_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s10147-021-01883-2","volume":"26","author":"K Ishitani","year":"2021","unstructured":"Ishitani K, Isoai A, Ito T et al (2021) Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. Int J Clin Oncol 26(6):1130\u20131138. https:\/\/doi.org\/10.1007\/s10147-021-01883-2","journal-title":"Int J Clin Oncol"},{"key":"2682_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46774-9","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Inui K, Hara Y et al (2019) Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-46774-9","journal-title":"Sci Rep"},{"key":"2682_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194873","author":"H Chen","year":"2021","unstructured":"Chen H, Ishihara M, Horita N et al (2021) Effectiveness of cell-free and concentrated ascites reinfusion therapy in the treatment of malignancy-related ascites: a systematic review and meta-analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13194873","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2682_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s10147-018-1371-7","volume":"24","author":"Y Kawata","year":"2019","unstructured":"Kawata Y, Nagasaka K, Matsumoto Y et al (2019) Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites. Int J Clin Oncol 24(4):420\u2013427. https:\/\/doi.org\/10.1007\/s10147-018-1371-7","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"2682_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/aor.13691","volume":"44","author":"K Matsusaki","year":"2020","unstructured":"Matsusaki K, Orihashi K (2020) Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites. Artif Organs 44(10):1090\u20131097. https:\/\/doi.org\/10.1111\/aor.13691","journal-title":"Artif Organs"},{"issue":"2","key":"2682_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.21873\/anticanres.16850","volume":"44","author":"Y Kim","year":"2024","unstructured":"Kim Y, Ajiki T, Ueda Y et al (2024) Reappraisal of a renovated cell-free and concentrated ascites reinfusion therapy for malignant ascites. Anticancer Res 44(2):613\u2013619. https:\/\/doi.org\/10.21873\/anticanres.16850","journal-title":"Anticancer Res"},{"issue":"1","key":"2682_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/1744-9987.12863","volume":"24","author":"T Ito","year":"2020","unstructured":"Ito T, Hanafusa N, Iwase S et al (2020) Ascitic IL-10 concentration predicts prognosis of patients undergoing cell-free and concentrated ascites reinfusion therapy. Ther Apher Dial 24(1):90\u201395. https:\/\/doi.org\/10.1111\/1744-9987.12863","journal-title":"Ther Apher Dial"},{"issue":"6","key":"2682_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nri3843","volume":"15","author":"SS Evans","year":"2015","unstructured":"Evans SS, Repasky EA, Fisher DT (2015) Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol 15(6):335\u2013349. https:\/\/doi.org\/10.1038\/nri3843","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2682_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.transci.2017.08.018","volume":"56","author":"T Ito","year":"2017","unstructured":"Ito T, Hanafusa N (2017) CART: cell-free and concentrated ascites reinfusion therapy against malignancy-related ascites. Transfus Apher Sci 56(5):703\u2013707. https:\/\/doi.org\/10.1016\/j.transci.2017.08.018","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"2682_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0885-3924(99)00138-4","volume":"19","author":"T Okuyama","year":"2000","unstructured":"Okuyama T, Akechi T, Kugaya A et al (2000) Development and validation of the cancer fatigue scale. J Pain Symptom Manag 19(1):5\u201314. https:\/\/doi.org\/10.1016\/s0885-3924(99)00138-4","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"2682_CR15","doi-asserted-by":"publisher","first-page":"7689","DOI":"10.1038\/s41598-021-86913-9","volume":"11","author":"T Seki","year":"2021","unstructured":"Seki T, Yanaihara N, Shapiro JS et al (2021) Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma. Sci Rep 11(1):7689. https:\/\/doi.org\/10.1038\/s41598-021-86913-9","journal-title":"Sci Rep"},{"issue":"12","key":"2682_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.injury.2007.10.003","volume":"38","author":"A Lenz","year":"2007","unstructured":"Lenz A, Franklin GA, Cheadle WG (2007) Systemic inflammation after trauma. Injury 38(12):1336\u20131345. https:\/\/doi.org\/10.1016\/j.injury.2007.10.003","journal-title":"Injury"},{"issue":"14","key":"2682_CR17","doi-asserted-by":"publisher","first-page":"11830","DOI":"10.3390\/ijms241411830","volume":"24","author":"B Weber","year":"2023","unstructured":"Weber B, Sturm R, Henrich D et al (2023) Diagnostic and prognostic potential of exosomal cytokines IL-6 and IL-10 in polytrauma patients. Int J Mol Sci 24(14):11830. https:\/\/doi.org\/10.3390\/ijms241411830","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2682_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jcla.20420","volume":"24","author":"\u0130H Celik","year":"2010","unstructured":"Celik \u0130H, Demirel FG, Uras N et al (2010) What are the cut-off levels for IL-6 and CRP in neonatal sepsis? J Clin Lab Anal 24(6):407\u2013412. https:\/\/doi.org\/10.1002\/jcla.20420","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"2682_CR19","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1152\/ajpendo.00074.2003","volume":"285","author":"A Steensberg","year":"2003","unstructured":"Steensberg A, Fischer CP, Keller C et al (2003) IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285(2):E433-437. https:\/\/doi.org\/10.1152\/ajpendo.00074.2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"13","key":"2682_CR20","first-page":"2165","volume":"45","author":"R Iwaki","year":"2018","unstructured":"Iwaki R, Shindo K, Kawahara H et al (2018) Cell-free ascites reinfusion Therapy (CART) modified by keisuke Matsusaki (KM-CART) at our Hospital. Gan To Kagaku Ryoho 45(13):2165\u20132167","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02682-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:48:09Z","timestamp":1740037689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02682-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2682"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02682-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}